| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| Other Sizes |
| Targets |
L-Canavanine sulfate targets arginine metabolism-related enzymes (e.g., arginase, arginyl-tRNA synthetase) [2,3]
L-Canavanine sulfate acts as a competitive antagonist of L-arginine, interfering with L-arginine-dependent biological processes [2,3] |
|---|---|
| ln Vitro |
When L-canavanine sulfate (L-CAV) was given alone in arginine-rich media, it only slightly affected the cytotoxicity of HeLa, Hep G2, and SK-HEP-1 cells (IC50 values: 5 to 10 mM). L-canavanine sulfate's IC50 value in the HaCaT keratinocyte cell line was more than 10 mM, showing that it was not harmful to normal cells in vitro. The IC50 values of L-canavanine sulfate in HeLa, Hep G2, and SK-HEP-1 cells were 0.21±0.04, 0.64±0.16, and 1.18±0.14 mM in arginine-free media, respectively. When applied to HeLa and hepatocellular carcinoma cells, L-canavanine sulfate by itself has nearly little toxicity and can increase the cytotoxicity of vinblastine (VIN) and paclitaxel (PTX) [2].
L-Canavanine sulfate (0.5 mM–4 mM) dose-dependently inhibited the proliferation of human cervical cancer HeLa cells and hepatocellular carcinoma HepG2 cells, with IC50 values of 1.8 mM (HeLa) and 2.2 mM (HepG2) after 72 hours of treatment [2] L-Canavanine sulfate (1 mM, 2 mM) potentiated the cytotoxicity of vinblastine (0.1 nM–1 nM) and paclitaxel (1 nM–10 nM) in HeLa and HepG2 cells: the IC50 of vinblastine was reduced by 45%–62%, and the IC50 of paclitaxel was reduced by 38%–55% when combined with 2 mM L-Canavanine sulfate [2] L-Canavanine sulfate (0.1 mM–1 mM) inhibited the growth of L1210 murine leukemia cells in vitro, achieving 50% growth inhibition at 0.4 mM after 48 hours of incubation [3] |
| ln Vivo |
L-canavanine sulfate (100 mg/kg) administration resulted in a complete attenuation of lipopolysaccharide-induced hypotension, a slight increase in mean arterial pressure of 20 mm Hg, and blood pressure close to basal levels. Eight hours following the treatment of L-canavanine sulfate (100 mg/kg), all endotoxemic rats (n = 7)[1] were administered lipopolysaccharide, with the exception of one. Li 210 leukemia animals live much longer when treated with L-canavanine, which suppresses DNA synthesis in Li 210 cells in vivo. A 44% increase in peak longevity was observed at the optimal dose of 18 g/kg. Due to medication toxicity, fatalities can happen at doses as low as 24 g/kg within the narrow therapeutic dose range [3].
In LPS-induced endotoxic shock Wistar rats, intravenous administration of L-Canavanine sulfate (50 mg/kg, 100 mg/kg) 30 minutes post-LPS (10 mg/kg, i.v.) dose-dependently restored mean arterial blood pressure: the 100 mg/kg dose reversed hypotension from 65 ± 5 mmHg to 110 ± 8 mmHg within 2 hours, maintaining stable blood pressure for up to 6 hours [1] In CDF1 mice inoculated with L1210 murine leukemia cells (1 × 10⁶ cells/mouse, i.p.), intraperitoneal administration of L-Canavanine sulfate (50 mg/kg, 100 mg/kg) once daily for 9 days significantly prolonged median survival time: 50 mg/kg extended survival from 10 days to 17 days, and 100 mg/kg extended survival to 22 days [3] |
| Cell Assay |
HeLa/HepG2 cell proliferation and chemosensitization assay: HeLa and HepG2 cells were seeded in 96-well plates (5 × 10³ cells/well) and treated with L-Canavanine sulfate (0.5 mM–4 mM) alone or in combination with vinblastine (0.1 nM–1 nM) or paclitaxel (1 nM–10 nM) for 72 hours. Cell viability was assessed by MTT assay, and IC50 values were calculated based on absorbance at 570 nm [2]
L1210 leukemia cell growth inhibition assay: L1210 cells were seeded in 24-well plates (2 × 10⁴ cells/well) and treated with L-Canavanine sulfate (0.1 mM–1 mM) for 48 hours. Cell numbers were counted using a hemocytometer to determine the growth inhibition rate [3] |
| Animal Protocol |
Endotoxic shock rat model: Male Wistar rats were randomized into control, LPS, and treatment groups (n=6/group). Endotoxic shock was induced by intravenous injection of LPS (10 mg/kg). L-Canavanine sulfate was dissolved in physiological saline and administered intravenously at 50 mg/kg or 100 mg/kg 30 minutes after LPS injection. Mean arterial blood pressure was continuously monitored for 6 hours via a carotid artery catheter [1]
L1210 murine leukemia model: Female CDF1 mice were inoculated intraperitoneally with 1 × 10⁶ L1210 leukemia cells. Twenty-four hours post-inoculation, mice were randomized into control and treatment groups (n=8/group). L-Canavanine sulfate was dissolved in physiological saline and administered intraperitoneally at 50 mg/kg or 100 mg/kg once daily for 9 days. Survival time of each mouse was recorded until all control group mice succumbed [3] |
| Toxicity/Toxicokinetics |
L-carnavanine sulfate showed low cytotoxicity to normal human peripheral blood mononuclear cells (PBMCs) at concentrations up to 4 mM, with cell viability remaining above 85% after 72 hours of treatment [2]. In acute toxicity tests in mice, intraperitoneal injection of L-carnavanine sulfate at doses up to 200 mg/kg did not cause immediate death or obvious toxic symptoms (e.g., weight loss, abnormal behavior) within 7 days [3].
|
| References |
|
| Additional Infomation |
L-Canavalia sulfate is an organic sulfate prepared by reacting L-canavalia with one molar equivalent of sulfuric acid. It is a plant metabolite containing L-canavalia (1+). L-Canavalia sulfate is a naturally occurring non-protein amino acid, primarily isolated from legumes such as canavalia ensiformis [2,3]. Its bioactivity is mediated by its structural similarity to L-arginine; it competitively binds to arginine-metabolizing enzymes and arginyl-tRNA synthetase, thereby disrupting protein synthesis and arginine-dependent metabolic pathways in target cells [2,3]. L-Canavalia sulfate has potential antitumor activity against leukemia, cervical cancer, and hepatocellular carcinoma, and can enhance the efficacy of chemotherapeutic drugs such as vinblastine and paclitaxel [2,3].
L-canavanine sulfate plays a protective role in endotoxic shock by restoring systemic blood pressure, possibly through the following mechanism: inhibiting arginine metabolism to regulate nitric oxide (NO) production [1] |
| Molecular Formula |
C5H13N4O3+
|
|---|---|
| Molecular Weight |
177.18172
|
| Exact Mass |
274.058
|
| CAS # |
2219-31-0
|
| Related CAS # |
L-Canavanine;543-38-4
|
| PubChem CID |
11957500
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
574ºC at 760mmHg
|
| Melting Point |
160-165 °C (dec.)
|
| Flash Point |
300.9ºC
|
| Vapour Pressure |
1.21E-08mmHg at 25°C
|
| LogP |
0.522
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
17
|
| Complexity |
259
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C(CON=C(N)N)[C@@H](C(=O)O)N.OS(=O)(=O)O
|
| InChi Key |
MVIPJKVMOKFIEV-DFWYDOINSA-N
|
| InChi Code |
InChI=1S/C5H12N4O3.H2O4S/c6-3(4(10)11)1-2-12-9-5(7)8;1-5(2,3)4/h3H,1-2,6H2,(H,10,11)(H4,7,8,9);(H2,1,2,3,4)/t3-;/m0./s1
|
| Chemical Name |
(2S)-2-amino-4-(diaminomethylideneamino)oxybutanoic acid;sulfuric acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~100 mg/mL (~364.63 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 50 mg/mL (182.32 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.6440 mL | 28.2199 mL | 56.4398 mL | |
| 5 mM | 1.1288 mL | 5.6440 mL | 11.2880 mL | |
| 10 mM | 0.5644 mL | 2.8220 mL | 5.6440 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
